Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study

BACKGROUND: To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected visual acuity (BCVA)<2/10 and/or second eye affected, regardless of BCVA. METHODS: In this 12-month, prospective, multice...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Ophthalmol
Main Authors: Bandello, Francesco, Staurenghi, Giovanni, Ricci, Federico, Midena, Edoardo, Viola, Francesco, Lupieri Sinibaldi, Tommaso, Colombo, Laura, Peruzzi, Elena, Bassanini, Stefania
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Clinical Science
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922014/
https://ncbi.nlm.nih.gov/pubmed/31079057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2019-313907
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki